Bruker Management

Management criteria checks 4/4

Bruker's CEO is Frank Laukien, appointed in Feb 1991, has a tenure of 33.17 years. total yearly compensation is $5.06M, comprised of 17.3% salary and 82.7% bonuses, including company stock and options. directly owns 27.68% of the company’s shares, worth €3.04B. The average tenure of the management team and the board of directors is 11.3 years and 8.5 years respectively.

Key information

Frank Laukien

Chief executive officer

US$5.1m

Total compensation

CEO salary percentage	17.3%
CEO tenure	33.2yrs
CEO ownership	27.7%
Management average tenure	11.3yrs
Board average tenure	8.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Frank Laukien's remuneration changed compared to Bruker's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	US$427m
Sep 30 2023	n/a	n/a	US$319m
Jun 30 2023	n/a	n/a	US$319m
Mar 31 2023	n/a	n/a	US$312m
Dec 31 2022	US$5m	US$873k	US$297m
Sep 30 2022	n/a	n/a	US$275m
Jun 30 2022	n/a	n/a	US$274m
Mar 31 2022	n/a	n/a	US$282m
Dec 31 2021	US$6m	US$812k	US$277m
Sep 30 2021	n/a	n/a	US$270m
Jun 30 2021	n/a	n/a	US$238m
Mar 31 2021	n/a	n/a	US$204m
Dec 31 2020	US$4m	US$689k	US$158m
Sep 30 2020	n/a	n/a	US$158m
Jun 30 2020	n/a	n/a	US$165m
Mar 31 2020	n/a	n/a	US$177m
Dec 31 2019	US$5m	US$753k	US$197m
Sep 30 2019	n/a	n/a	US$207m
Jun 30 2019	n/a	n/a	US$189m
Mar 31 2019	n/a	n/a	US$184m
Dec 31 2018	US$4m	US$731k	US$180m
Sep 30 2018	n/a	n/a	US$98m
Jun 30 2018	n/a	n/a	US$92m
Mar 31 2018	n/a	n/a	US$84m
Dec 31 2017	US$5m	US$704k	US$79m

Compensation vs Market: Frank's total compensation ($USD5.06M) is about average for companies of similar size in the German market ($USD5.66M).

Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.

CEO

Frank Laukien (63 yo)

33.2yrs

Tenure

US$5,057,195

Compensation

Dr. Frank H. Laukien, Ph D., serves as the Chairman, Chief Executive Officer and President of Bruker Corporation at Bruker BioSpin GmbH since February 1991. Dr. Laukien serves as the Chairman, Chief Execut...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Gerald Herman	Executive VP & CFO	6.1yrs	US$2.20m	0.029% $ 3.2m
Mark Munch	Corporate Executive VP and President of Bruker Nano Group & Corporate	8.8yrs	US$2.73m	0.048% $ 5.3m
Juergen Srega	President of Bruker CALID Group & Bruker Daltonics Division	11.3yrs	US$1.47m	0.079% $ 8.7m
Falko Busse	President of Bruker BioSpin Group	5.9yrs	US$1.35m	0.015% $ 1.7m
Frank Laukien	Chairman	33.2yrs	US$5.06m	27.68% $ 3.0b
Justin Ward	Senior Director of Investor Relations & Corporate Development	no data	no data	no data
J. Alldredge	General Counsel & Secretary	no data	no data	no data
Stacey Desrochers	Treasurer & Director of Investor Relations	16.1yrs	no data	no data
Burkhard Prause	President and CEO of Bruker Energy & Supercon Technologies	16yrs	US$967.91k	0.0077% $ 843.7k

11.3yrs

Average Tenure

61yo

Average Age

Experienced Management: BKD's management team is seasoned and experienced (11.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Frank Laukien	Chairman	33.2yrs	US$5.06m	27.68% $ 3.0b
John Ornell	Independent Director	8.7yrs	US$241.01k	0.014% $ 1.6m
Robert Rosenthal	Independent Director	8.4yrs	US$224.01k	0.014% $ 1.6m
Richard Packer	Independent Director	16.9yrs	US$229.01k	0.049% $ 5.4m
William Linton	Independent Lead Director	24.2yrs	US$231.01k	0.023% $ 2.5m
Adelene Perkins	Independent Director	6.9yrs	US$224.01k	0.013% $ 1.4m
Hermann Requardt	Independent Director	8.7yrs	US$219.01k	0.014% $ 1.6m
Bonnie Anderson	Independent Director	3.6yrs	US$214.01k	0.0053% $ 579.7k
Cynthia Friend	Independent Director	7.9yrs	US$214.01k	0.0080% $ 876.7k
Philip Ma	Independent Director	2yrs	US$154.52k	0.0025% $ 271.7k

8.5yrs

Average Tenure

65yo

Average Age

Experienced Board: BKD's board of directors are considered experienced (8.5 years average tenure).

Bruker Management

Management criteria checks 4/4

Key information

Recent management updates

Bruker Corporation, Annual General Meeting, May 30, 2024

Insider recently sold €760k worth of stock

Insufficient new directors

Executive VP & CFO recently sold €983k worth of stock

Independent Director recently sold €775k worth of stock

Chairman recently bought €93k worth of stock

Recent updates

Bruker Corporation to Report Q1, 2024 Results on May 02, 2024

Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference

Bruker Corporation, Annual General Meeting, May 30, 2024

Now 22% undervalued

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies

Bruker Corporation Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO

Bruker Corporation (NasdaqGS:BRKR) completed the acquisition of Chemspeed Technologies AG.

Insider recently sold €760k worth of stock

Tecfin S.À R.L. entered into an agreement to acquire Identicare Limited from Tecfin S.À R.L. for €870 million.

Fourth quarter dividend of US$0.05 announced

Investor sentiment improves as stock rises 16%

Bruker Corporation Approves Payment of A Quarterly Cash Dividend, Payable on March 15, 2024

Bruker Corporation Provides Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings released: EPS: US$2.92 (vs US$2.00 in FY 2022)

Bruker Corporation (NasdaqGS:BRKR) acquired Nanophoton Corporation.

Bruker Corporation to Report Q4, 2023 Results on Feb 13, 2024

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire Chemspeed Technologies AG.

Bruker Corporation (NasdaqGS:BRKR) acquired Tornado Spectral Systems.

Bruker Corporation Announces Quarterly Dividend, Payable on December 15, 2023

Bruker Corporation Revises Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings released: EPS: US$0.60 (vs US$0.60 in 3Q 2022)

Bruker Corporation to Report Q3, 2023 Results on Nov 02, 2023

Now 22% undervalued after recent price drop

Bruker Corporation Introduces Next-Generation Nanomechanical Test System

Insufficient new directors

Bruker Introduces Novel 4D-Proteomics™ Timstof® Capabilities

Bruker Corporation Provides Revenue Guidance for Fiscal Year 2023

Upcoming dividend of US$0.05 per share at 0.3% yield

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire all of the outstanding shares of PhenomeX Inc. (NasdaqGS:CELL).

Bruker Corporation Approves Payment of Quarterly Cash Dividend in on the Company’s Common Stock, Payable on September 15, 2023

Bruker Corporation Raises Financial Outlook for Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.39 (vs US$0.33 in 2Q 2022)

Bruker Corporation to Report Q2, 2023 Results on Aug 03, 2023

Bruker Announces SciY Platform of Advanced Scientific and Automation Software Solutions for the Digital Transformation of the Life Science and Biopharma Industries

Bruker Corporation Announces New D6 PHASER Benchtop X-Ray Diffraction Platform for Materials Analysis and Advanced Research

Executive VP & CFO recently sold €983k worth of stock

Bruker CorporationIntroduces Novel EVOQ™ DART-TQ+ for Chromatography-Free Mass Spectrometry Aimed at the Applied Market Segments

Independent Director recently sold €775k worth of stock

Bruker Corporation (NasdaqGS:BRKR) announces an Equity Buyback for $500 million worth of its shares.

Bruker Corporation (NasdaqGS:BRKR) acquired ZONTAL, Inc.

First quarter 2023 earnings released: EPS: US$0.52 (vs US$0.41 in 1Q 2022)

Bruker Corporation Raises Financial Outlook for Fiscal Year 2023

Bruker Corporation Approves Quarterly Dividend, Payable on March 17, 2023

Full year 2022 earnings released: EPS: US$2.00 (vs US$1.83 in FY 2021)

Bruker Corporation Provides Revenue Guidance for Fiscal Year 2023

Bruker Corporation to Report Q4, 2022 Results on Feb 09, 2023

Bruker Corporation Provides Revenue Guidance for the Fourth Quarter of Fiscal Year 2022 and Full Fiscal Year 2023

Bruker Corporation (NasdaqGS:BRKR) acquired Acquifer Imaging Gmbh.

Bruker Corporation (NasdaqGS:BRKR) acquired an unknown majority stake in Biognosys AG.

Bruker Corporation (NasdaqGS:BRKR) acquired Neurescence Inc.

Upcoming dividend of US$0.05 per share

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire Neurescence Inc.

Bruker Corporation Announces Quarterly Dividend, Payable on December 16, 2022

Bruker Corporation (NasdaqGS:BRKR) acquired Inscopix, Inc.

Third quarter 2022 earnings released: EPS: US$0.60 (vs US$0.57 in 3Q 2021)

Bruker Corporation Provides Earnings Guidance for the Year of 2022

Bruker Corporation to Report Q3, 2022 Results on Nov 03, 2022

Bruker Launches New nanoElute® 2 nano-LC For 4D-Proteomics, Advances Fluxomics Applications with MetaboScape® 2023 Software

Upcoming dividend of US$0.05 per share

Bruker Corporation Introduces Enabling New Scientific Capabilities for Cell Biology and Pathobiology Research with High-Field NMR Innovations

Bruker Approves Payment of Quarterly Cash Dividend, Payable September 16, 2022

Second quarter 2022 earnings released: EPS: US$0.33 (vs US$0.38 in 2Q 2021)

Bruker Corporation Provides Earnings Guidance for the Year 2022

Bruker Corporation to Report Q2, 2022 Results on Aug 03, 2022

Bruker Corporation Launches NMR-Based Molecular Phenomics Clinical Research Tool for ‘Long Covid’ Multi-Organ Risk Assessment

Bruker Presents High-Value Life Science, Materials Research and Applied Market Solutions At Analytica 2022

Bruker Corporation Introduces Enhanced 3D Holographic Stimulation for Optogenetics on its Ultima 2Pplus Multiphoton Microscope

Bruker Launches timsTOF HT with Greater Dynamic Range for Further Enhancing Unbiased, High-Confidence 4D Proteomics(TM)

Upcoming dividend of US$0.05 per share